Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DNP-019

            Therapeutic Area: Infections and Infectious Diseases Product Name: DNP-019

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Dinona

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 21, 2020

            Details:

            Under this agreement, Samsung and Dinona will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

            Deal Size: $3.6 million Upfront Cash: Undisclosed

            Deal Type: Funding May 18, 2020

            Details:

            SK Bioscience plans to discuss how to use the funding for development of covid-19 vaccine with the Coalition for Epidemic Preparedness Innovations, a global alliance that has been coordinating the worldwide vaccine development effort for COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Themis Bioscience

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 11, 2020

            Details:

            Themis and ABL Europe have signed an agreement under which ABL will manufacture Themis' vaccine candidate in preparation for clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NK cell therapy,Antibody recruiting molecule

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Kleo Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 31, 2020

            Details:

            Kleo's first non-oncology application of its antibody recruiting molecule (ARM™) to be tested in combination with GCLC'S NK cells as a potential COVID-19 therapeutic.